These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34174414)

  • 21. Fosphenytoin use in children.
    Pellock JM
    Neurology; 1996 Jun; 46(6 Suppl 1):S14-6. PubMed ID: 8649608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-Dependent Decline in Serum Phenytoin Concentration With Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese: A Retrospective Study.
    Ohno Y; Niwa T; Hirai K; Suzuki K; Yamada Y; Hayashi Y; Hayashi H; Suzuki A; Itoh Y
    Ther Drug Monit; 2018 Aug; 40(4):507-511. PubMed ID: 29683874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.
    Ogutu BR; Newton CR; Muchohi SN; Otieno GO; Edwards G; Watkins WM; Kokwaro GO
    Br J Clin Pharmacol; 2003 Jul; 56(1):112-9. PubMed ID: 12848783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intramuscular use of fosphenytoin: an overview.
    Uthman BM; Wilder BJ; Ramsay RE
    Neurology; 1996 Jun; 46(6 Suppl 1):S24-8. PubMed ID: 8649611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.
    Lai CM; Moore P; Quon CY
    Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):51-62. PubMed ID: 7620838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats.
    Burstein AH; Cox DS; Mistry B; Eddington ND
    Epilepsy Res; 1999 Apr; 34(2-3):129-33. PubMed ID: 10210027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin.
    Ramsay RE; Wilder BJ; Uthman BM; Garnett WR; Pellock JM; Barkley GL; Leppik IE; Knapp LE
    Epilepsy Res; 1997 Oct; 28(3):181-7. PubMed ID: 9332883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children.
    Clay JL; Fountain NB
    Expert Rev Neurother; 2022 Jan; 22(1):1-13. PubMed ID: 34726961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit.
    Muchohi SN; Kokwaro GO; Maitho TE; Munenge RW; Watkins WM; Edwards G
    Eur J Drug Metab Pharmacokinet; 2002; 27(2):83-9. PubMed ID: 12064376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.
    Inoue Y; Usui N; Hiroki T; Shimizu K; Kobayashi S; Shimasaki S
    Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):139-48. PubMed ID: 22968854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucuronidation of prodrug reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin.
    Annesley TM; Kurzyniec S; Nordblom GD; Buchanan N; Pool W; Reily M; Talaat R; Roberts WL
    Clin Chem; 2001 May; 47(5):910-8. PubMed ID: 11325896
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Probabilistic approach to the establishment of maximal content limits of impurities in drug formulations: the case of parenteral diphenylhydantoic acid.
    Manca D; Walker RM; Krishna G; Graziano MJ; Kropko ML
    Regul Toxicol Pharmacol; 1999 Feb; 29(1):1-14. PubMed ID: 10051414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol.
    Bebin M; Bleck TP
    Drugs; 1994 Aug; 48(2):153-71. PubMed ID: 7527321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absorption rate limit considerations for oral phosphate prodrugs.
    Heimbach T; Oh DM; Li LY; Forsberg M; Savolainen J; Leppänen J; Matsunaga Y; Flynn G; Fleisher D
    Pharm Res; 2003 Jun; 20(6):848-56. PubMed ID: 12817887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery.
    Wilder BJ; Campbell K; Ramsay RE; Garnett WR; Pellock JM; Henkin SA; Kugler AR
    Arch Neurol; 1996 Aug; 53(8):764-8. PubMed ID: 8759983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays.
    Kugler AR; Annesley TM; Nordblom GD; Koup JR; Olson SC
    Clin Chem; 1998 Jul; 44(7):1474-80. PubMed ID: 9665426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin.
    Dasgupta A; Havlik D
    Ther Drug Monit; 1998 Dec; 20(6):658-62. PubMed ID: 9853983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs.
    Varia SA; Stella VJ
    J Pharm Sci; 1984 Aug; 73(8):1080-7. PubMed ID: 6548519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin.
    Roberts WL; De BK; Coleman JP; Annesley TM
    Clin Chem; 1999 Jun; 45(6 Pt 1):829-37. PubMed ID: 10351992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Tolerability, and Pharmacokinetics of Fosphenytoin Loading in Patients With Subarachnoid Hemorrhage.
    Kim DW; Kim TE; Ji M; Chun YI
    Clin Neuropharmacol; 2015; 38(6):248-51. PubMed ID: 26536021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.